NLRP3 and metabolic dysfunction-associated steatohepatitis: Differences between our findings and prior studies are likely due to differences in the mouse models of NASH that were employed in each study, and only future human studies can resolve whether inhibiting Nlrp3 specifically or all inflammasomes via caspase-1 inhibition can improve human NASH histology—which would also indirectly suggest which experimental design reflects the human condition most closely.